0
USD
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Patient Derived Xenograft"

From
EUR$2,999USDGBP
From
EUR$3,825USDGBP
EUR$4,500USDGBP
From
EUR$4,750USDGBP
From
EUR$3,300USDGBP
From
EUR$3,250USDGBP
EUR$4,850USDGBP
From
EUR$4,949USDGBP
From
EUR$3,825USDGBP
EUR$4,500USDGBP
Patient Derived Xenograft Market 2021-2025 - Product Thumbnail Image

Patient Derived Xenograft Market 2021-2025

  • Report
  • December 2021
  • 120 Pages
  • Global
From
EUR$2,500USDGBP
From
EUR$4,750USDGBP
From
EUR$4,750USDGBP
From
EUR$4,150USDGBP
Loading Indicator

The Patient Derived Xenograft (PDX) market is a rapidly growing segment of the drug discovery industry. PDX models are derived from human tumors that are implanted into immunodeficient mice, allowing researchers to study the effects of drugs on human cancer in a living system. PDX models are used to identify new drug targets, evaluate drug efficacy, and assess drug safety. They are also used to study the biology of cancer and to develop personalized treatments. PDX models are increasingly being used in clinical trials to evaluate the efficacy of new drugs. PDX models offer several advantages over traditional cell-based models, including the ability to study the effects of drugs on a living system, the ability to study the effects of drugs on multiple tumor types, and the ability to study the effects of drugs on the tumor microenvironment. Companies in the PDX market include Charles River Laboratories, Crown Bioscience, Horizon Discovery, and Taconic Biosciences. Show Less Read more

This website uses cookies to ensure you get the best experience. Learn more